Skip to main content

Advertisement

Table 2 Response of MM cell lines towards various treatments

From: Estrogenic or antiestrogenic therapies for multiple myeloma?

Cell lines Compounds Ref.
  2ME2 Tam 4HT Tor Ral ICI RU  
ANBL6 CCA + Ap.*        [5]
Karpas 620    No      [11]
        No **
KAS-6/1 CCA + Ap.        [5]
KMM-1   CCA + Ap.   CCA + Ap.     [10]
LP-1    CCA + Ap.      [11]
       CCA CCA **
MM.1S/R Ap.        [4]
NCI-H929    CCA + Ap.      [11]
       Ap. Ap. **
OCI-My5 CCA + Ap.        [4]
   CCA + Ap.       [5]
OPM-2    No      [11]
       CCA CCA **
RPMI 8226 Ap.        [4]
  CCA        [5]
    CCA + Ap.      [11]
  CCA + Ap.   CCA + Ap. No   CCA + Ap.   [12]
   CCA + Ap.    CCA + Ap.    [13]
       Ap. Ap. **
U266   CCA + Ap.   CCA + Ap.     [10]
    CCA + Ap.      [11]
   CCA + Ap. CCA + Ap.    CCA + Ap.   [12]
   CCA + Ap.    CCA + Ap.    [14]
       No No **
  1. Presented cell lines were chosen as in Table 1. Cell lines were treated in vitro with micromolar concentrations of 2ME2, SERMs or SERDs (0.5–50 μM) and drug effects were detected 24–72 h later. Cell cycle arrest was demonstrated essentially by flow cytometry sorting of propidium iodide-stained cells, apoptosis was assessed with different techniques such as annexin V staining, caspase activity assays, mitochondrial membrane potential measurement, and TUNEL method. * CCA, cell cycle arrest; Ap., apoptosis; Tam, tamoxifene; Tor, toremifene, Ral, raloxifene. ** Gauduchon et al, submitted.